

1-800-533-1710

PATIENT NAME TESTING, CTCP		PATIENT NU	MBER		AGE 33	SEX M	ACCESSION # G9145000
ORDERING PHYSICIAN	,	CLIENT ORD	ER#	,			ACCOUNT # LIAISONS
COLLECTION 02/23/10 08:24 A DATE TIME Test Client	RECEIVED 02/23/10 0 DATE	REPORT PRI 03/09/10 DATE	NTED 09:37 A TIME	SPECIMEN INFORMA DATE OF BIRTH:	TION		
Attn: Mayo Liaisons 200 First Street SW Rochester, MN 55905 507-284-8202							

н

TEST REQUESTED LO REF RANGE PERFORM SITE *

Circulating Tumor Cells, Prostate

 Specimen
 Whole Blood
 MCR

 Specimen ID
 1050004
 MCR

 Order Date
 24 Feb 2010 13:07
 MCR

 Result
 MCR

Negative, 0 circulating tumor cells/7.5 mL of blood.

Interpretation MCR

The results of this test are negative (<5 circulating tumor cells/7.5 mL of blood).

Previous CellSearch Specimens (up to 5):

DATE	# CTCs	RESULT
11/02/2009	0	Negative

In patients with metastatic prostate cancer, negative results are predictive of longer progression free survival (PFS).

In one prospective study, circulating tumor cells (CTCs) were enumerated in the peripheral blood of 231 patients with castration-resistant prostate cancer (CRPC), before starting chemotherapy and monthly thereafter. Patients were stratified into unfavorable and favorable prognostic groups based on CTC levels of 5 or more, or less then 5 CTCs/7.5 mL, respectively. Patients with unfavorable pretreatment CTC (57%) had shorter overall survival (OS) (median OS, 11.5 versus 21.7 months; Cox hazard ratio, 3.3; P < 0.0001). Unfavorable post-treatment CTC counts also predicted shorter OS at 2 to 5, 6 to 8, 9 to 12, and 13 to 20 weeks (median OS, 6.7-9.5 versus 19.6-20.7 months; Cox hazard ratio,

* Perform Site Legend on last page of report

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, CTCP	Final	02/23/10 08:24 A



1-800-533-1710

PATIENT NAME			PATIENT NU	MBER		AGE	SEX	ACCESSION #
TESTING, CTCP						33	М	G9145000
ORDERING PHYSICIAN		CLIENT ORDER #					ACCOUNT #	
2011 5071011	DEGEN/ED		DEDORT DO	NTED	ODEOMEN INCODIA	TION		LIAISONS
COLLECTION	RECEIVED		REPORT PRI		SPECIMEN INFORMA	IION		
02/23/10 08:24 A	02/23/10 0	18:24 A	03/09/10	09:37 A	DATE OF BIRTH:			
DATE TIME	DATE	TIME	DATE	TIME				
Test Client								
Attn: Mayo Liaisons								
•								
200 First Street SW								
Rochester, MN 55905								
507-284-8202								

н

TEST REQUESTED LO

REF RANGE

PERFORM SITE *

MCR

3.6-6.5; P < 0.0001). CTC counts predicted OS better than PSA decrement algorithms at all time points; area under the receiver operator curve for CTC was 81% to 87% and 58% to 68% for 30% PSA reduction (P = 0.0218). Prognosis for patients with (a) unfavorable baseline CTC who converted to favorable CTC improved (6.8 to 21.3 months); (b) favorable baseline CTC who converted to unfavorable worsened (>26 to 9.3 months). CTCs are an accurate and independent predictor of OS in CRPC.

1) de Bono JS et al. Clin Cancer Res. 14:6302-9, 2008.

Reason For Referral

Assess for Circulating Tumor Cells

Method MCR

CellSearch (TM) System

Reviewed By MCR

Kevin Carl Halling MD, PhD

Release Date 24 Feb 2010 13:45 MCR

* PERFORMING SITE

MCR Mayo Clinic Dpt of Lab Med & Pathology
200 First Street SW Rochester, MN 55905

Lab Director: Franklin R. Cockerill, III, M.D.

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, CTCP	Final	02/23/10 08:24 A